Sept 28 (Reuters) – Mirum Pharmaceuticals on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study.
Here are some key details:
• Mirum was testing brelovitug, an experimental monoclonal antibody that binds to the hepatitis B surface antigen, a protein found on the surface of the virus
• The company was testing the treatment for chronic hepatitis delta virus, a liver infection that affects only people already infected with hepatitis B
• The disease can cause severe symptoms that can lead to liver damage and even death. It affects about 230,000 people in the US and Europe, the company estimates
• At 24 weeks, 56% of patients who were given 300 milligrams of brelovitug and 45% of patients who were given 900 milligrams achieved a reduction of the hepatitis D virus and normal liver enzyme levels, compared with 0% in the delayed treatment group, the company said.
• Treatment with brelovitug was well tolerated across dose groups, with a safety profile consistent with previously reported data, Mirum said.
• Full results from the study will be presented at an upcoming medical congress, with the company expecting to submit a marketing application for the drug to the US FDA in the first half of 2027.
(Reporting by Sneha S K in Bengaluru; Editing by Jonathan Ananda)
